JP7870252B2 - 再開通療法後の再灌流傷害又は出血を処置するための組成物及び方法 - Google Patents
再開通療法後の再灌流傷害又は出血を処置するための組成物及び方法Info
- Publication number
- JP7870252B2 JP7870252B2 JP2022554288A JP2022554288A JP7870252B2 JP 7870252 B2 JP7870252 B2 JP 7870252B2 JP 2022554288 A JP2022554288 A JP 2022554288A JP 2022554288 A JP2022554288 A JP 2022554288A JP 7870252 B2 JP7870252 B2 JP 7870252B2
- Authority
- JP
- Japan
- Prior art keywords
- tetrafluoro
- trifluoromethylbenzylamino
- composition
- use according
- neronemdaz
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/482—Serine endopeptidases (3.4.21)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2026018547A JP2026082994A (ja) | 2020-03-11 | 2026-02-06 | 再開通療法後の再灌流傷害又は出血を処置するための組成物及び方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062988187P | 2020-03-11 | 2020-03-11 | |
| US62/988,187 | 2020-03-11 | ||
| PCT/IB2021/000136 WO2021181159A1 (en) | 2020-03-11 | 2021-03-10 | Compositions and methods for treating reperfusion injury or hemorrhage after recanalization therapy |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2026018547A Division JP2026082994A (ja) | 2020-03-11 | 2026-02-06 | 再開通療法後の再灌流傷害又は出血を処置するための組成物及び方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023517566A JP2023517566A (ja) | 2023-04-26 |
| JP2023517566A5 JP2023517566A5 (cg-RX-API-DMAC7.html) | 2024-03-19 |
| JP7870252B2 true JP7870252B2 (ja) | 2026-06-04 |
Family
ID=77665492
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022554288A Active JP7870252B2 (ja) | 2020-03-11 | 2021-03-10 | 再開通療法後の再灌流傷害又は出血を処置するための組成物及び方法 |
| JP2026018547A Pending JP2026082994A (ja) | 2020-03-11 | 2026-02-06 | 再開通療法後の再灌流傷害又は出血を処置するための組成物及び方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2026018547A Pending JP2026082994A (ja) | 2020-03-11 | 2026-02-06 | 再開通療法後の再灌流傷害又は出血を処置するための組成物及び方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US11826329B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4117648A4 (cg-RX-API-DMAC7.html) |
| JP (2) | JP7870252B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20230010187A (cg-RX-API-DMAC7.html) |
| CN (1) | CN115515573A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2021233206A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112022018136A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3174709A1 (cg-RX-API-DMAC7.html) |
| CO (1) | CO2022014343A2 (cg-RX-API-DMAC7.html) |
| IL (2) | IL296288B2 (cg-RX-API-DMAC7.html) |
| MX (2) | MX2022011214A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021181159A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12285182B2 (en) | 2018-10-10 | 2025-04-29 | Innova Vascular, Inc. | Devices and methods for removing an embolus |
| US11826329B2 (en) | 2020-03-11 | 2023-11-28 | Gnt Pharma Co., Ltd. | Compositions and methods for treating reperfusion injury or hemorrhage after recanalization therapy |
| CN113995723B (zh) * | 2020-07-27 | 2025-02-18 | 浙江普洛家园药业有限公司 | 一种索法地尔冻干粉针剂的制备方法及其产品和用途 |
| KR20240142433A (ko) * | 2021-12-28 | 2024-09-30 | 주식회사 지엔티파마 | 폐 장애를 치료하기 위한 조성물 및 방법 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2005529972A (ja) | 2002-06-19 | 2005-10-06 | ニューロテック カンパニー リミテッド | テトラフルオロベンジル誘導体及びこれを含有する急性及び退行性脳神経系疾患の予防及び治療用薬学的組成物 |
| JP2006515370A (ja) | 2003-01-20 | 2006-05-25 | ニューロテック ファーマシューティカルズ カンパニー リミテッド | ニューロトロフィンによって誘導される細胞壊死の抑制方法 |
| JP2008546642A (ja) | 2005-05-25 | 2008-12-25 | チョンワエ ファーマ コーポレーション | 置換テトラフルオロベンジルアニリン化合物、及びその薬学的に許容される塩の製造方法 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20060121721A (ko) * | 2005-05-23 | 2006-11-29 | 주식회사 중외제약 | 테트라플루오로벤질 유도체 또는 그의 염을 함유하는주사제용 조성물 |
| KR101523345B1 (ko) * | 2008-04-28 | 2015-05-28 | 주식회사 지엔티파마 | 재관류 손상의 치료 또는 예방용 약학 조성물 |
| CN102617383A (zh) | 2012-03-20 | 2012-08-01 | 横店集团家园化工有限公司 | 索法地尔晶型、制备方法及包含索法地尔晶体的无菌粉末 |
| JP2018502894A (ja) | 2015-01-27 | 2018-02-01 | アストラゼネカ アクチボラグ | 心筋梗塞の病歴がある患者においてアテローム血栓性イベントを治療または予防する方法 |
| US11826329B2 (en) | 2020-03-11 | 2023-11-28 | Gnt Pharma Co., Ltd. | Compositions and methods for treating reperfusion injury or hemorrhage after recanalization therapy |
-
2021
- 2021-03-10 US US17/197,736 patent/US11826329B2/en active Active
- 2021-03-10 WO PCT/IB2021/000136 patent/WO2021181159A1/en not_active Ceased
- 2021-03-10 CA CA3174709A patent/CA3174709A1/en active Pending
- 2021-03-10 JP JP2022554288A patent/JP7870252B2/ja active Active
- 2021-03-10 AU AU2021233206A patent/AU2021233206A1/en active Pending
- 2021-03-10 CN CN202180032761.3A patent/CN115515573A/zh active Pending
- 2021-03-10 KR KR1020227034966A patent/KR20230010187A/ko active Pending
- 2021-03-10 EP EP21768391.1A patent/EP4117648A4/en active Pending
- 2021-03-10 MX MX2022011214A patent/MX2022011214A/es unknown
- 2021-03-10 IL IL296288A patent/IL296288B2/en unknown
- 2021-03-10 BR BR112022018136A patent/BR112022018136A2/pt unknown
- 2021-03-10 IL IL309923A patent/IL309923A/en unknown
-
2022
- 2022-09-09 MX MX2025012439A patent/MX2025012439A/es unknown
- 2022-10-07 CO CONC2022/0014343A patent/CO2022014343A2/es unknown
-
2023
- 2023-08-21 US US18/235,986 patent/US12433861B2/en active Active
-
2025
- 2025-09-10 US US19/324,355 patent/US20260027076A1/en active Pending
-
2026
- 2026-02-06 JP JP2026018547A patent/JP2026082994A/ja active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2005529972A (ja) | 2002-06-19 | 2005-10-06 | ニューロテック カンパニー リミテッド | テトラフルオロベンジル誘導体及びこれを含有する急性及び退行性脳神経系疾患の予防及び治療用薬学的組成物 |
| JP2006515370A (ja) | 2003-01-20 | 2006-05-25 | ニューロテック ファーマシューティカルズ カンパニー リミテッド | ニューロトロフィンによって誘導される細胞壊死の抑制方法 |
| JP2008546642A (ja) | 2005-05-25 | 2008-12-25 | チョンワエ ファーマ コーポレーション | 置換テトラフルオロベンジルアニリン化合物、及びその薬学的に許容される塩の製造方法 |
Non-Patent Citations (2)
| Title |
|---|
| Hong, J.M. et al.,Safety and Optimal Neuroprotection of neu2000 in acute Ischemic stroke with reCanalization: study protocol for a randomized, double-blinded, placebo-controlled, phase-II trial,Trials,2018年,19, 375,1-7,DOI:10.1186/s13063-018-2746-9 |
| 大木 宏一 他,診療ガイドライン 脳卒中ガイドライン 2015,日本内科学会雑誌,106巻, 5号,980-985 |
Also Published As
| Publication number | Publication date |
|---|---|
| IL296288B1 (en) | 2024-02-01 |
| CA3174709A1 (en) | 2021-09-16 |
| US20260027076A1 (en) | 2026-01-29 |
| EP4117648A1 (en) | 2023-01-18 |
| EP4117648A4 (en) | 2024-05-29 |
| IL296288A (en) | 2022-11-01 |
| CO2022014343A2 (es) | 2023-02-16 |
| JP2023517566A (ja) | 2023-04-26 |
| US20210283080A1 (en) | 2021-09-16 |
| CN115515573A (zh) | 2022-12-23 |
| IL309923A (en) | 2024-03-01 |
| IL296288B2 (en) | 2024-06-01 |
| US11826329B2 (en) | 2023-11-28 |
| MX2022011214A (es) | 2022-10-07 |
| AU2021233206A1 (en) | 2022-10-06 |
| WO2021181159A1 (en) | 2021-09-16 |
| JP2026082994A (ja) | 2026-05-19 |
| BR112022018136A2 (pt) | 2022-10-25 |
| US20230390231A1 (en) | 2023-12-07 |
| KR20230010187A (ko) | 2023-01-18 |
| US12433861B2 (en) | 2025-10-07 |
| MX2025012439A (es) | 2025-11-03 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RD01 | Notification of change of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7426 Effective date: 20221220 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20221220 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240308 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20240308 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20250219 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20250311 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20250610 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20251007 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20260206 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20260423 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20260525 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7870252 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |